Lindesfarne LLC discloses 8.6% stake in Lakewood-Amedex

Lindesfarne LLC reports beneficial ownership of 203,360 shares of Lakewood-Amedex Biotherapeutics Inc. common stock on a Schedule 13G. This represents 8.582% of the class, with sole voting and sole dispositive power over all 203,360 shares and no shared power.

Rhea-AI Filing Summary

Lindesfarne LLC reports beneficial ownership of 203,360 shares of Lakewood-Amedex Biotherapeutics Inc. common stock on a Schedule 13G. This represents 8.582% of the class, with sole voting and sole dispositive power over all 203,360 shares and no shared power.

The filing states that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Lakewood-Amedex Biotherapeutics Inc., and are not held in connection with any transaction having that purpose or effect.

Key Figures

Shares beneficially owned: 203,360 shares Percent of class: 8.582% Sole voting power: 203,360 shares +3 more

6 metrics

Shares beneficially owned 203,360 shares Amount beneficially owned by Lindesfarne LLC

Percent of class 8.582% Percent of Lakewood-Amedex Biotherapeutics Inc. common stock class

Sole voting power 203,360 shares Shares over which Lindesfarne LLC has sole power to vote

Shared voting power 0 shares Shares over which Lindesfarne LLC has shared power to vote

Sole dispositive power 203,360 shares Shares over which Lindesfarne LLC has sole power to dispose

Shared dispositive power 0 shares Shares over which Lindesfarne LLC has shared power to dispose

Key Terms

beneficially owned, sole power to vote, sole power to dispose, dispositive power, +1 more

5 terms

beneficially owned financial

"Item 4. | Ownership (a) | Amount beneficially owned: 203,360"

Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.

sole power to vote financial

"(i) Sole power to vote or to direct the vote: 203,360"

sole power to dispose financial

"(iii) Sole power to dispose or to direct the disposition of: 203,360"

dispositive power financial

"Sole Dispositive Power 203,360.00 8 | Shared Dispositive Power 0.00"

Dispositive power is the authority to decide the final outcome of an asset, legal claim, contract, or corporate action — in effect the power to dispose of or resolve something. For investors it matters because whoever holds that authority can determine who gets paid, who controls an asset or vote, and how risks and returns are allocated; think of it like holding the key that lets you lock in the winner or loser in a deal.

Schedule 13G regulatory

""securities referred to above" in a Schedule 13G context"

A Schedule 13G is a formal document that investors file with the government when they acquire a large ownership stake in a company, usually for investment purposes rather than control. It helps keep the public informed about who owns significant parts of a company's shares, which can influence how the company is managed and how investors make decisions. Filing this schedule is important for transparency and understanding the ownership landscape of publicly traded companies.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What ownership stake in LABT does Lindesfarne LLC report on this Schedule 13G?

Lindesfarne LLC reports beneficial ownership of 203,360 shares of Lakewood-Amedex Biotherapeutics Inc. common stock, representing 8.582% of the class, with sole voting and sole dispositive power over all reported shares.

Does Lindesfarne LLC have sole or shared voting power over LABT shares?

Lindesfarne LLC reports sole voting power over 203,360 shares and no shared voting power. It also reports sole dispositive power over the same 203,360 shares and no shared dispositive power.

Is Lindesfarne LLC seeking to influence control of Lakewood-Amedex Biotherapeutics Inc. (LABT)?

The filer certifies the securities were not acquired and are not held for changing or influencing control of Lakewood-Amedex Biotherapeutics Inc., and are not held in connection with any transaction having that control-related purpose or effect.

What class of LABT securities does the Schedule 13G for Lindesfarne LLC cover?

The Schedule 13G filed by Lindesfarne LLC covers common stock of Lakewood-Amedex Biotherapeutics Inc., identified by CUSIP 51255A102, and reports beneficial ownership and voting/dispositive powers over that class.

Where is Lindesfarne LLC, the LABT shareholder, organized and located?

Lindesfarne LLC is a U.S. entity with citizenship listed as USA and is organized in Nevada, with its principal business office at 7004 Stanhope Place, University Park, Florida 34201.

Who signed the Schedule 13G reporting Lindesfarne LLC’s LABT holdings?

The Schedule 13G was signed by Steve Parkinson, identified as Managing Member of Lindesfarne LLC, certifying the accuracy of the ownership information and the passive investment intent statement.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/06/2026 - 02:19 PM Accepted by SEC EDGAR 08/06/2026 - 02:18 PM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Lakewood-Amedex Biotherapeutics Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

51255A102

(CUSIP Number)

04/17/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 51255A102

1

Names of Reporting Persons

LINDESFARNE LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

NEVADA

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 203,360.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 203,360.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

203,360.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

9.88 %

12

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Lakewood-Amedex Biotherapeutics Inc.
(b)	Address of issuer's principal executive offices: 8031 COOPER CREEK BOULEVARD, UNIT 103, UNIVERSITY PARK, FLORIDA, 34201
Item 2.
(a)	Name of person filing: Lindesfarne LLC
(b)	Address or principal business office or, if none, residence: 7004 STANHOPE PLACE, UNIVERSITY PARK, FLORIDA, 34201
(c)	Citizenship: USA
(d)	Title of class of securities: Common Stock
(e)	CUSIP Number(s): 51255A102
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 203,360
(b)	Percent of class: 8.582 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 203,360
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 203,360
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

LINDESFARNE LLC

Signature:	/s/ Steve Parkinson
Name/Title:	Managing Member
Date:	08/06/2026